PMID- 20733612
OWN - NLM
STAT- MEDLINE
DCOM- 20110224
LR  - 20101111
IS  - 1476-5608 (Electronic)
IS  - 1365-7852 (Linking)
VI  - 13
IP  - 4
DP  - 2010 Dec
TI  - Effect of intermittent fasting on prostate cancer tumor growth in a mouse model.
PG  - 350-5
LID - 10.1038/pcan.2010.24 [doi]
AB  - Caloric restriction (CR) has been shown to have anti-cancer properties. However, 
      CR may be difficult to apply in humans secondary to compliance and potentially 
      deleterious effects. An alternative is intermittent CR, or in the extreme case 
      intermittent fasting (IF). In a previous small pilot study, we found 2 days per 
      week of IF with ad libitum feeding on the other days resulted in trends toward 
      prolonged survival of mice bearing prostate cancer xenografts. We sought to 
      confirm these findings in a larger study. A total of 100 (7- to 8-week-old) male 
      severe combined immunodeficiency mice were injected subcutaneously with 1 x 10(5) 
      LAPC-4 prostate cancer cells. Mice were randomized to either ad libitum Western 
      Diet (44% carbohydrates, 40% fat and 16% protein) or ad libitum Western Diet with 
      twice-weekly 24 h fasts (IF). Tumor volumes and mouse bodyweights were measured 
      twice weekly. Mice were killed when tumor volumes reached 1000 mm(3). Serum and 
      tumor were collected for analysis of the insulin/insulin-like growth factor 1 
      (IGF-1) hormonal axis. Overall, there was no difference in mouse survival 
      (P=0.37) or tumor volumes (P >/= 0.10) between groups. Mouse body weights were 
      similar between arms (P=0.84). IF mice had significantly higher serum IGF-1 
      levels and IGF-1/IGFBP-3 ratios at killing (P<0.001). However, no difference was 
      observed in serum insulin, IGFBP-3 or tumor phospho-Akt levels (P >/= 0.39). IF did 
      not improve mouse survival nor did it delay prostate tumor growth. This may be 
      secondary to metabolic adaptations to the 24 h fasting periods. Future studies 
      are required to optimize CR for application in humans.
FAU - Thomas, J A 2nd
AU  - Thomas JA 2nd
AD  - Division of Urologic Surgery, Department of Surgery, Duke Prostate Center, Duke 
      University Medical Center, Durham, NC 27710, USA.
FAU - Antonelli, J A
AU  - Antonelli JA
FAU - Lloyd, J C
AU  - Lloyd JC
FAU - Masko, E M
AU  - Masko EM
FAU - Poulton, S H
AU  - Poulton SH
FAU - Phillips, T E
AU  - Phillips TE
FAU - Pollak, M
AU  - Pollak M
FAU - Freedland, S J
AU  - Freedland SJ
LA  - eng
PT  - Journal Article
DEP - 20100824
PL  - England
TA  - Prostate Cancer Prostatic Dis
JT  - Prostate cancer and prostatic diseases
JID - 9815755
SB  - IM
MH  - Animals
MH  - Body Weight/physiology
MH  - Caloric Restriction
MH  - Carcinoma/*diet therapy/mortality/*pathology
MH  - Cell Line, Tumor
MH  - *Cell Proliferation
MH  - Disease Models, Animal
MH  - Fasting/*physiology
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Periodicity
MH  - Prostatic Neoplasms/*diet therapy/mortality/*pathology
MH  - Survival Analysis
MH  - Tumor Burden
MH  - Xenograft Model Antitumor Assays
EDAT- 2010/08/25 06:00
MHDA- 2011/02/25 06:00
CRDT- 2010/08/25 06:00
PHST- 2010/08/25 06:00 [entrez]
PHST- 2010/08/25 06:00 [pubmed]
PHST- 2011/02/25 06:00 [medline]
AID - pcan201024 [pii]
AID - 10.1038/pcan.2010.24 [doi]
PST - ppublish
SO  - Prostate Cancer Prostatic Dis. 2010 Dec;13(4):350-5. doi: 10.1038/pcan.2010.24. 
      Epub 2010 Aug 24.